D. E. Shaw & Co. Inc. Sells 289,713 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

D. E. Shaw & Co. Inc. lessened its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 28.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 733,551 shares of the life sciences company's stock after selling 289,713 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.95% of Integra LifeSciences worth $16,637,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Quadrant Capital Group LLC grew its position in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC boosted its position in Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares during the period. Nisa Investment Advisors LLC boosted its position in Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares during the period. Covestor Ltd boosted its position in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Integra LifeSciences during the fourth quarter valued at about $180,000. Institutional investors own 84.78% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities cut their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company dropped their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Finally, Truist Financial decreased their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $18.63.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded up $0.56 on Friday, reaching $13.57. The company's stock had a trading volume of 956,151 shares, compared to its average volume of 1,048,070. Integra LifeSciences Holdings Co. has a 52-week low of $11.60 and a 52-week high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a 50-day simple moving average of $17.99 and a 200 day simple moving average of $21.70. The company has a market cap of $1.05 billion, a P/E ratio of -150.76, a PEG ratio of 0.73 and a beta of 1.27.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million for the quarter, compared to analysts' expectations of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 earnings per share. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.